Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09DWL
|
|||
| Former ID |
DAP000266
|
|||
| Drug Name |
Zaleplon
|
|||
| Synonyms |
Sonata; Zalaplon; Zerene; CL 284846; L 846; L846; LJC 10846; ZAL 846; AZ-007; CL 284,846; CL-284846; CL284,846; L-846; LJC-10846; SKP-1041; Sonata (TN); Staccato-zaleplon; Starnoc (TN); ZAL-846; Zaleplon [USAN:INN]; Zaleplon (JAN/USAN/INN); N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide; N-(3-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-N-ethylacetamide; 3'-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)-N-ethylacetanilide; 3'-(3-Cyanopyrazolo(1,5-alpha)pyrimidin-7-yl)-N-ethylacetanilide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Insomnia [ICD-11: 7A00-7A0Z] | Approved | [1], [2] | |
| Therapeutic Class |
Hypnotics and Sedatives
|
|||
| Company |
King Pharm
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H15N5O
|
|||
| Canonical SMILES |
CCN(C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C#N)C(=O)C
|
|||
| InChI |
1S/C17H15N5O/c1-3-21(12(2)23)15-6-4-5-13(9-15)16-7-8-19-17-14(10-18)11-20-22(16)17/h4-9,11H,3H2,1-2H3
|
|||
| InChIKey |
HUNXMJYCHXQEGX-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 151319-34-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9687, 5366116, 7847596, 8153504, 12014056, 14751928, 26719706, 29216208, 29224756, 46386657, 46508267, 48416707, 49831110, 49858710, 50064487, 57288874, 57322911, 58107163, 76325725, 81041179, 81093138, 87246409, 92308631, 92714203, 93166204, 103558703, 104179081, 104310058, 104829286, 124360324, 124659160, 125341659, 126629628, 126655581, 126669582, 128115429, 131299907, 134337580, 135017416, 135698186, 135710033, 136352570, 136897476, 137001621, 142240621, 144089038, 144205425, 160964301, 162011443, 162022385
|
|||
| ChEBI ID |
CHEBI:10102
|
|||
| ADReCS Drug ID | BADD_D02379 | |||
| SuperDrug ATC ID |
N05CF03
|
|||
| SuperDrug CAS ID |
cas=151319345
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides dorei DSM 17855
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Zaleplon can be metabolized by Bacteroides dorei DSM 17855 (log2FC = -0.807; p = 0.013). | |||
|
Studied Microbe: Bacteroides fragilis ATCC43859
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Zaleplon can be metabolized by Bacteroides fragilis ATCC43859 (log2FC = -0.568; p = 0.041). | |||
|
Studied Microbe: Bacteroides fragilis HMW 610
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Zaleplon can be metabolized by Bacteroides fragilis HMW 610 (log2FC = -0.519; p = 0.014). | |||
|
Studied Microbe: Bacteroides fragilis HMW 615
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Zaleplon can be metabolized by Bacteroides fragilis HMW 615 (log2FC = -0.407; p = 0.016). | |||
|
Studied Microbe: Bacteroides fragilis NCTC 9343
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Zaleplon can be metabolized by Bacteroides fragilis NCTC 9343 (log2FC = -0.56; p = 0.011). | |||
|
Studied Microbe: Bacteroides uniformis ATCC 8492
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Zaleplon can be metabolized by Bacteroides uniformis ATCC 8492 (log2FC = -0.394; p = 0.045). | |||
|
Studied Microbe: Bacteroides vulgatus ATCC 8482
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Zaleplon can be metabolized by Bacteroides vulgatus ATCC 8482 (log2FC = -0.668; p = 0.015). | |||
|
Studied Microbe: Bacteroides xylanisolvens DSM18836
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Zaleplon can be metabolized by Bacteroides xylanisolvens DSM18836 (log2FC = -0.466; p = 0.009). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia hansenii DSM20583
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Zaleplon can be metabolized by Blautia hansenii DSM20583 (log2FC = -0.448; p = 0.032). | |||
|
Studied Microbe: Clostridium sp.
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Zaleplon can be metabolized by Clostridium sp. (log2FC = -0.438; p = 0.01). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | GABA(A) receptor alpha-1 (GABRA1) | Target Info | Modulator | [4] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Retrograde endocannabinoid signaling | ||||
| GABAergic synapse | ||||
| Morphine addiction | ||||
| Nicotine addiction | ||||
| Reactome | Ligand-gated ion channel transport | |||
| GABA A receptor activation | ||||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | ||||
| Iron uptake and transport | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4345). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 077237. | |||
| REF 3 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.